News About: Pharm. Industry


24 incrementally modified drugs newly approved last year, increased by 33%

The number of incrementally modified drugs approved last year was the total 24 products, increased by 33% compared to the year of 2015. The Ministry of Food and Drug Safety revealed that 24 products were approved as ...

Female CEOs’ ‘Outstanding performance’ in management, marketing and R&D at listed pharmas

Although the female executive ratio is only 7% in listed pharmaceutical companies, they are evaluated to have outstanding performance with their active activities. According to the Yakup Shinmoon’s(www.yakup.com) ana...

Celltrion’s active launching process for Truxima, starting to sell in Germany

Celltrion announced on the 18th that it has started to prepare for an official launch of ‘Truxima,’ the first antibody biosimilar for the treatment of blood cancer, even in Germ...

Bukwang Pharm acquires joint license of Meditoxin Inj for treatment purpose from Eisai

Bukwang Pharm announced that it signed a co-marketing and distribution agreement with Eisai Korea for the co-sales and exclusive distribution license of ‘Meditoxin Inj 200 Units...

Dong Wha Pharm acquires license to sell all the GSK’s OTC products worth of KRW 55 billion

Dong Wha Pharm has risen as the strongest in selling OTC drugs. According to the industry concerned, Dong Wha Pharm was known to sign an agreement of selling all the GSK’s OTC products(total 10 products) with GSK on ...

Female ratio to total executives was only 7% in listed pharmas

Less than 1 of 10 executives working for Korean listed pharmaceutical companies were women. According to the Yakup Shinmoon’s(www.yakup.com) analysis result of the executive status(including registered and unregister...

Hanmi Pharm acquires world’s first approval of combination drug for treatment of both asthma and allergic rhinitis

Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kown) announced on the 17th that it acquired commercialization approval of ‘Monterizine,’ a combination drug for patients with both asthma and allergic rhinitis(allergic rhiniti...

Intensified polarization in R&D investment among listed pharms

Although it is estimated there were more than 6 listed pharmaceutical companies investing more than KRW 100 billion into R&D in a year, there were also a number of pharmaceutical products spending less than 1% of thei...

Celltrion records KRW 196.6 billion sales and KRW 89.4 billion operating profits

Celltrion announced on the 11th that it recorded KRW 196.578 billion sales in the 1st quarter of 2017, increased by 81.2% compared to the same quarter of the last year. Its operating profits were KRW 89.394 billion i...

Ildong’s chronic hepatitis B treatment ‘Besivo Tab’ become 28th Korean new drug

Ildong Pharmaceutical(CEO Woong-Sup Yoon) acquired approval of ‘Besivo Tab(generic name: besifovir dipivoxil maleat),’ a new chronic hepatitis B treatment developed by on its ow...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.